Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 63%
Sell 25%
Strong Sell 0%

Bulls say

RxSight is a commercial-stage medical technology company that offers intraocular lens technology for improved vision after cataract surgery. Despite a decline in revenue and earnings in the latest quarter, management has reiterated their revenue guidance for 2026 and expects improvement in utilization and cash burn. Potential upside drivers include faster LDD installed base growth, higher utilization, and margin improvement, leading to a Buy rating from the analyst. However, risks include limited adoption, disappointing commercial execution, competition in the IOL market, and potential for dilutive financing.

Bears say

RxSight is facing a number of risks that could inhibit the company's growth, including limited product adoption due to the need for additional capital equipment, potential for increased competition in the intraocular lens market, and potential financing challenges. Despite relatively strong financials, with a 77.5% gross margin and reduced operating expenses, the company's recent revenue growth has slowed, and overall market share in the premium category remains relatively low. Finally, while the collaboration with ALC may bring in significant upfront cash and development milestones, there is uncertainty around the potential commercialization and royalty payments for this partnership.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 63% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.